Peer-reviewed veterinary case report
Ultrasound shows how GnRH antagonist affects enlarged dog prostate
By D'Francisco, F et al.·Published in Theriogenology·2020·National University of La Plata·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Quantitative bidimentional and Doppler ultrasound assessment of the effect of a GnRH antagonist on canine prostatic hyperplasia.
- Species:
- dog
Plain-English summary
A group of seven mixed-breed male dogs, aged around 11 years, were treated with a medication called acyline to help reduce symptoms of benign prostatic hyperplasia (BPH), which is an enlargement of the prostate. After receiving the treatment, the dogs showed a significant decrease in prostate size and improvements in blood flow and tissue characteristics over the next 30 days. By the end of the treatment period, the dogs had a mean reduction of about 38% in prostate volume, and any cysts present in the prostate disappeared. This suggests that a single dose of acyline can effectively manage BPH symptoms in dogs, and regular monthly treatments may be a safe option for ongoing care.
People also search for: dog prostate enlargement treatment · acyline for dog BPH · symptoms of prostate problems in dogs
Abstract
The objectives of this article were: a) To describe the effect of a single administration of the third generation GnRH antagonist, acyline, on canine benign prostatic hyperplasia (BPH) b)To quantitatively compare parenchyma echogenicity, heterogeneity (SD echogenicity) and blood flow in hyperplastic and treated prostate glands. Seven mixed bred dogs, 11.14 ± 0.8 years of age, weighing 8.5 ± 1.4 (3.8-15.6) kg, with BPH were included in this study and administered acyline 330 mg/kg sc (day 0). Then the dogs were examined by B Mode and Doppler ultrasound on days 15, 30 and 60 after treatment. Parenchymal frozen images were digitally analyzed. On day -7, prostatic volume was 1.60-5.36 fold (volume ratio) enlarged in relation to the expected volume. Prostatic volume decreased up to a mean of -38.44% (P < 0.01; range -32.2 to -70.9%) on day 30 to gradually increase towards pretreatment values. A correlation between volume ratio and nadir treatment volume was also found (r = - 0.87; P < 0.05). Mean parenchyma echogenicity (P < 0.01) and heterogeneity (P < 0.01) diminished in all the post treatment evaluations. Pretreatment intraprostatic cysts disappeared at the time point of peak treatment effect. Prostatic arteries RI increased on day 30, being different from day -7 and also from day 60 values (P < 0.05). It was concluded that a single administration of a third generation GnRH antagonist safely decreased prostatic volume and parenchyma and blood flow abnormities associated with canine BPH during 30 days. Monthly administrations of this treatment could represent a rapid, efficient and safe therapeutic option for BPH.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/31901534/